CAPRCapricor Therapeutics, Inc.

$30.40+229% 1Y

$30.40

$3.8452 weeks$35.34

The financials

Capricor Therapeutics, Inc. by the numbers

For the full year FY2025, revenue was $0 (−100% year on year) and net income −$105M. The next results filing is expected around Nov 9, 2026, the same week as a year ago.

Capricor Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statement	Q2 2026	Q2 2025	Change
Operating income	−$43M	−$28M	n/a
Net income	−$41M	−$26M	n/a
Diluted EPS	−$0.70	−$0.57	n/a

On our screens:Most shorted stocks

Biotechnology

Ranks #66 of 196 by RyuScore

Compare peers

SNDX+0.59%

Syndax Pharmaceuticals, Inc.

ZYME+2.2%

Zymeworks Inc.

RXRX+10%

Recursion Pharmaceuticals, Inc.

GHRS+2.8%

GH Research PLC

TSHA+1.6%

Taysha Gene Therapies, Inc.

ANAB-0.50%

AnaptysBio, Inc.